Skip to Content
Merck

HPLC Analysis of CYP3A Inhibitors on Ascentis® Express RP-Amide

HPLC Analysis of CYP3A Inhibitors on Ascentis® Express RP-Amide application for HPLC

Materials

analytical column

Product No.
Description
Pricing

53913-U

Ascentis® Express RP-Amide, 2.7 μm HPLC Column

2.7 μm particle size, L × I.D. 10 cm × 2.1 mm

mobile phase component

Product No.
Description
Pricing

70221

Ammonium formate

eluent additive for LC-MS, LiChropur™, ≥99.0%

standard

Product No.
Description
Pricing

N5536

Nefazodone hydrochloride

≥98% (HPLC), solid

S6319

Sertraline hydrochloride

≥98% (HPLC)

1279804

Fluoxetine hydrochloride

United States Pharmacopeia (USP) Reference Standard

1285909

Fluvoxamine maleate

United States Pharmacopeia (USP) Reference Standard

PHR1285

Lovastatin

Pharmaceutical Secondary Standard; Certified Reference Material

CONDITIONS

column

Ascentis Express RP-Amide, 10 cm x 2.1 mm I.D., 2.7 μm particles (53913-U)

mobile phase

[A] 20 mM ammonium formate in 50:50 (v/v) water:acetonitrile

flow rate

0.6 mL/min

column temp.

35 °C

detector

ESI(+), m/z 100-600

injection

1 μL

Description

Analysis Note

This application demonstrates the suitability of the Ascentis Express RP Amide for the analysis of CYP3A Inhibitors.

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

Chromatogram Search

Related Product Categories

HPLC ColumnsGC Columns & AccessoriesTLC Plates & AdsorbentsSolid Phase Microextraction (SPME)Solid Phase Extraction & QuEChERS

Related Applications

Small Molecule HPLCLarge Molecule HPLCGas Chromatography (GC)TLCSolid Phase Microextraction (SPME)Solid Phase Extraction (SPE)QuEChERS